Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$1.27 - $2.28 $59,616 - $107,027
-46,942 Reduced 31.86%
100,401 $129,000
Q2 2023

Aug 11, 2023

BUY
$1.44 - $2.19 $18,630 - $28,334
12,938 Added 9.63%
147,343 $253,000
Q1 2023

May 15, 2023

SELL
$1.17 - $2.7 $20,672 - $47,706
-17,669 Reduced 11.62%
134,405 $243,000
Q4 2022

Feb 13, 2023

BUY
$2.38 - $3.55 $80,436 - $119,979
33,797 Added 28.57%
152,074 $404,000
Q3 2022

Nov 14, 2022

BUY
$3.14 - $4.87 $10,980 - $17,030
3,497 Added 3.05%
118,277 $391,000
Q2 2022

Aug 12, 2022

BUY
$3.03 - $5.32 $147,760 - $259,435
48,766 Added 73.87%
114,780 $417,000
Q1 2022

May 13, 2022

SELL
$4.66 - $7.66 $7,866 - $12,930
-1,688 Reduced 2.49%
66,014 $336,000
Q4 2021

Feb 08, 2022

BUY
$6.82 - $17.8 $93,236 - $243,343
13,671 Added 25.3%
67,702 $516,000
Q3 2021

Nov 15, 2021

BUY
$13.62 - $19.48 $735,902 - $1.05 Million
54,031 New
54,031 $800,000

Others Institutions Holding ATAI

About ATAI Life Sciences N.V.


  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $197M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.